🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to researchers.

An International Public Health Issue

Gonorrhoea infections are escalating around the world, with data suggesting over 82 million new cases annually. Particularly high rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the reality of rising global incidence, the spread of superbugs and the very limited treatment choices at this time.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts hope that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in close succession. This medication, which is also used to treat UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This milestone signifies a huge turning point in the management of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Results and Worldwide Availability

As per findings published in a prominent scientific publication, zoliflodacin cured the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which combines a dual-drug approach. The study enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in numerous developing nations.

Doctors on the front lines have shared hope. Having a one-pill regimen such as this is described as a "critical tool" for managing the epidemic. This is viewed as essential to alleviate the strain of the infection for people and to prevent the spread of untreatable gonorrhoea globally.